Creative Planning Invests $116,000 in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Creative Planning bought a new stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,272 shares of the company’s stock, valued at approximately $116,000.

A number of other hedge funds have also recently bought and sold shares of ORIC. Zurcher Kantonalbank Zurich Cantonalbank grew its position in ORIC Pharmaceuticals by 162.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock worth $36,000 after buying an additional 3,188 shares in the last quarter. Quest Partners LLC lifted its position in ORIC Pharmaceuticals by 253.2% in the second quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock worth $73,000 after purchasing an additional 7,440 shares during the period. ProShare Advisors LLC acquired a new stake in ORIC Pharmaceuticals during the first quarter worth $161,000. Virtu Financial LLC acquired a new position in shares of ORIC Pharmaceuticals in the 1st quarter valued at $225,000. Finally, XTX Topco Ltd bought a new position in shares of ORIC Pharmaceuticals during the 2nd quarter worth about $153,000. 95.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ORIC. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. HC Wainwright reiterated a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, November 4th. Stifel Nicolaus initiated coverage on shares of ORIC Pharmaceuticals in a research report on Friday, September 6th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Oppenheimer cut their target price on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $18.29.

ORIC Pharmaceuticals Price Performance

Shares of NASDAQ:ORIC opened at $10.26 on Wednesday. The stock has a market cap of $723.76 million, a price-to-earnings ratio of -5.86 and a beta of 1.13. The company has a 50 day moving average of $9.71 and a 200-day moving average of $9.32. ORIC Pharmaceuticals, Inc. has a one year low of $5.85 and a one year high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Equities research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.8 earnings per share for the current year.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.